I was wondering why SNY did nit. If you are selling, a little PR helps. Yet they have done nothing. Perhaps Novartis was trying to temper the effect the announcement would have on MNTA. The 12% royalty is actually higher beyond the $100,000 range(aprox). So MNTA is not hurt (in this respect)as much as predicted.
A "Never-Mind" moment. Sorry disregard the above. I misread the announcement. MNTA still gets only 10 -12% if there is a third enox on the market. And if MNTA is the only generic they have to make $135,000,000 before they get the 45%. Did they actually pay a lawyer for this?